Opinion on R&D

Published within

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Phase Forward/Veritas: tackling data bottlenecks

Phase Forward and Veritas aim to increase efficiency in patient recruitment, by using Internet-enabled data management systems. The system should be an easy sell to pharma companies, as it tackles bottlenecks that can slow clinical trials and thus a drug's time to market.

Published By Datamonitor
05 Apr 2002
Expert View
Expert View

Pharmacogenomics: the only thing to fear is fear itself

Revenue opportunities are going begging because of the pharmaceutical industry's reluctance to invest in pharmacogenomics, according to new research. Lower clinical development costs and promotional expenses could see opportunities in smaller markets increase dramatically, with pharmacogenomics-based diagnostics forcing companies to re-evaluate their R&D planning.

Published By Datamonitor
24 Feb 2003
CommentWire
CommentWire

Pharmacia: much-touted Semaxanib fails trials

The anti-angiogenesis drug was ineffective at combating colorectal cancer, and its maker has now aborted the trial. It looks like Pharmacia may also stop Semaxinib's trials for other indications, dropping the drug altogether in favor of other small molecular therapies.

Published By Datamonitor
11 Feb 2002
CommentWire
CommentWire

Pharmacia: Cerebrex trial data to boost COX-II revenues

The data suggests that Pharmacia's market leading pain drug is as effective as other popular anti-inflammatory products. Cerebrex, a COX-II inhibitor, also has an improved side effect profile over traditional compounds. The results should further boost the COX-II inhibitor class, but may do less to help Cerebrex in its battle with rival COX-II Vioxx.

Published By Datamonitor
15 Nov 2001
CommentWire
CommentWire

Pharmacia: Bextra may not be best for dysmenorrhea

Research suggests that Bextra is as effective as the older NSAID, naproxen, for the treatment of primary dysmenorrhea. It's not clear on current evidence that the advantages the newer COX-II inhibitors offer for this indication really justify their costs - but at least in the US, DTC marketing could gain them significant market share anyway.

Published By Datamonitor
07 Aug 2002
CommentWire
CommentWire

Pharmacia: Bextra bests postoperative pain

The possible broadening of indications for Pharmacia's new second-generation COX-II inhibitor will obviously increase potential revenue. It should also decrease Bextra's cannibalization of Pharmacia's first generation COX-II inhibitor, Celebrex, by increasing the differentiation between the two drugs.

Published By Datamonitor
14 Feb 2002
Expert View
Expert View

Pharmaceutical Licensing Weekly Review: August 26 - 30, 2002

Last week's licensing news illustrated the instability of relationships between the pharmaceutical organizations. Whilst Dusa Pharmaceuticals, Schering AG, Alliance Pharmaceutical and Baxter Healthcare were all involved in agreements that were brought to an end Novartis, QLT and Sanofi-Synthelabo were able to extend and continue existing partnerships.

Published By Datamonitor
30 Aug 2002
Expert View
Expert View

Pharmaceutical Licensing Weekly Review: August 19 - 23, 2002

Last week's licensing news featured three of the world's biggest pharmaceutical companies: first GlaxoSmithKline joined Pfizer in an alliance with Argonaut, then Pharmacia joined forces with BattellePharma. Johns Hopkins University also had a busy week beating out deals with Crucell and Correlogic Systems. Finally Amgen and Praecis agreed to terminate their failed relationship.

Published By Datamonitor
23 Aug 2002
CommentWire
CommentWire

Pharma R&D: struggling to replace the blockbusters

Many current blockbusters are due for patent expiry, and so new drugs are needed to replace them. Some firms, like AstraZeneca, are in a strong position to do this. However, five top tier companies - including Roche and J&J - currently have no late stage development potential. To keep growing, they will need to source new drugs through in-licensing or M&A.

Published By Datamonitor
19 Jun 2002
CommentWire
CommentWire

Pharma blockbusters: bigger isn't always better

Pharma companies have been highly reliant on billion-dollar drugs for growth. But the impact of blockbusters on meeting growth targets is set to diminish. Instead, companies must boost the size and quality of their drug portfolios through licensing, alliances or possible mergers. They will also need to manage their drug lifecycles more effectively.

Published By Datamonitor
23 Apr 2002

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

No help is available.